FAQs
Q1. How does Myo-inositol in Advibe Sachet help women with PCOS — what is the actual mechanism?
A1. Myo-inositol is a naturally occurring cyclitol that serves as a second messenger for insulin receptor signalling. In PCOS, there is frequently a defect in inositol phosphoglycan (IPG) mediators, which causes insulin resistance even in lean women — the insulin signal fails to translate correctly at the cellular level. Supplementing with Myo-inositol restores the signalling pathway, improving insulin sensitivity, reducing compensatory hyperinsulinaemia, and consequently lowering the elevated androgen (testosterone, DHEA-S) levels that drive many PCOS symptoms: irregular cycles, facial hair, acne, and anovulation. Multiple randomised controlled trials confirm that Myo-inositol supplementation at 2–4g daily improves ovulation frequency, menstrual regularity, and clinical androgen markers.
Q2. Why does Advibe Sachet combine Myo-inositol with Vitamin D3 — what does Vitamin D3 add for PCOS?
A2. Vitamin D deficiency is disproportionately prevalent in women with PCOS and correlates with worse insulin resistance, higher androgen levels, and poorer ovarian response. Vitamin D3 receptors are expressed in granulosa cells of ovarian follicles — adequate Vitamin D3 supports normal follicular development and improves the chance of ovulation. It also independently improves insulin sensitivity through VDR-mediated gene transcription. The combination of Myo-inositol (correcting insulin signalling) and Vitamin D3 (correcting the often co-existing deficiency) addresses two distinct but overlapping root causes of PCOS metabolic dysfunction.
Q3. Can Advibe Sachet be taken alongside Metformin prescribed by a gynaecologist for PCOS?
A3. Myo-inositol and Metformin both improve insulin sensitivity but through different mechanisms — Metformin primarily works by reducing hepatic glucose output and activating AMPK, while Myo-inositol corrects the IPG signalling defect upstream of the insulin receptor. Several clinical studies have compared and combined them, showing that Myo-inositol can achieve comparable improvements in metabolic and hormonal markers to Metformin with fewer gastrointestinal side effects, and that the combination may be superior to either alone. That said, never change or combine prescription medications without explicit guidance from your gynaecologist or endocrinologist.
Q4. Can Advibe Sachet help with PCOS-related acne and skin concerns beyond reproductive health?
A4. Yes — the acne and oiliness associated with PCOS are driven by elevated androgens, particularly DHEA-S and free testosterone, which stimulate sebaceous glands. As Myo-inositol reduces insulin-driven androgen production over 8–12 weeks of use, sebaceous gland activity decreases, leading to visibly reduced acne and skin oiliness in many women. This is a hormonal mechanism that topical acne products cannot address, making Advibe a relevant complement to a dermatologist's acne regimen for women with known or suspected PCOS.
Q5. How long does Advibe Sachet need to be taken before menstrual cycles become more regular?
A5. Clinical studies typically show measurable improvements in ovulation frequency and hormonal markers within 12–16 weeks of consistent daily use. Menstrual cycle regularity is one of the earlier responding parameters; fertility markers take longer to normalise. Consistent daily use is essential — skipping doses interrupts the steady-state inositol concentrations needed to restore IPG signalling. Most gynaecologists recommend a minimum 3-month trial before evaluating response, with continuation for 6–12 months if fertility is the goal. Use as a nutraceutical supplement and always under your healthcare provider's supervision.
